Peanut Allergy Clinical Trial

The UNC’s Food Allergy Initiative is conducting an industry-sponsored phase one clinical trial for peanut allergy. The purpose of this study is to find out if an investigational treatment for peanut allergy is safe and tolerable for people suffering from peanut allergy.

The product being investigated is a liquid extract which is injected under the skin in your arm. The drug being used for this study, HAL-MPE1, is not yet approved by the U.S. Food and Drug Administration (FDA).

You may be eligible for this study if you:

  • Are between 18 and 50 years of age
  • Have a diagnosed peanut allergy

You should not participate in this study if you:

  • Have any severe uncontrolled disease (lung, endocrine, renal, cardiac, or immune) or disease which prevents you from using epinephrine
  • Are pregnant or nursing
  • Are currently receiving immunotherapy treatment
  • Have participated in any interventional study for peanut immunotherapy in the last year

Other criteria will be determined over the phone with a study coordinator and at the first clinic visit.

The study participation will require you to attend our UNC clinic for 18 visits over a period of 22-27 weeks. Most visits will last approximately 4 hours. Study participants will be paid up to $2,000 to compensate for time needed for completion of all study activities. A parking voucher will be given to cover the cost of parking at each visit.

It is important to know that this letter is not telling you to join this study. Your participation is voluntary. If you would like to learn more about this study, please contact the study coordinator, Lauren Herlihy, RN, MSN, at 919-962-4406 or .

This research study has been approved by the Biomedical UNC-CH IRB: Study #16-1650

Click here for a flyer to print/share.

Filed under: